Abbott develops healthcare products across medical devices, diagnostics, nutrition, and branded generic pharmaceuticals in certain international markets. Its devices include FreeStyle Libre continuous glucose monitors and cardiovascular technologies; diagnostics include laboratory and rapid testing systems. Abbott also sells nutritional products such as Ensure and Similac, creating a diversified mix of equipment, consumables, and consumer-oriented healthcare products.
Abbott Laboratories (ABT) has a MarketKingdoms composite score of 60.9 (B-), an B-range rating. It ranks 1210th of 1,866 covered companies, 60th of 78 in Healthcare (sector average 64.4) and 6th of 10 in Medical Devices. Scores as of 2026-10-26.
Its strongest lenses are Stock selection at 87 (Healthcare average 79) and KPI momentum at 86 (Healthcare average 78). Its weakest lenses are Trend (momentum) at 25 (sector average 50) and Quality (profitability) at 46 (sector average 50).
| Lens | Type | ABT | Healthcare average | Medical Devices average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 77 | 81 | 77 | 44th |
| Stock selection | Research signal | 87 | 79 | 78 | 97th |
| KPI momentum | Research signal | 86 | 78 | 75 | 73rd |
| Catalyst watch | Research signal | 77 | 74 | 75 | 72nd |
| Price (valuation) | Fundamental lens | 49 | 50 | 54 | 47th |
| Expansion (growth) | Fundamental lens | 49 | 50 | 57 | 55th |
| Quality (profitability) | Fundamental lens | 46 | 50 | 53 | 51st |
| Trend (momentum) | Fundamental lens | 25 | 50 | 27 | 21st |
The most recent call analysed was held on 2026-10-21 (fiscal 2026 Q3). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -6.4%: its price is below the path its market, sector and industry moves explain (undervalued versus the model path). Factor sensitivity: market beta 0.41, sector beta 0.09, industry beta 0.64; the factor model explains 49% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| DexCom Inc. (DXCM) | 70.3 | B+ | -25.0% |
| Edwards Lifesciences Corp. (EW) | 64.0 | B- | +1.7% |
| STERIS plc (STE) | 63.9 | B- | -7.7% |
| Zimmer Biomet Holdings Inc. (ZBH) | 62.9 | B- | -12.1% |
| Medtronic Plc (MDT) | 62.6 | B- | -5.9% |
| GE HealthCare Technologies Inc. (GEHC) | 60.5 | B- | -5.8% |
| Stryker Corp. (SYK) | 59.3 | B- | -3.3% |
| Insulet Corp. (PODD) | 59.2 | B- | -18.8% |
Abbott Laboratories financial statements · Healthcare sector ranking · Medical Devices industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.